Efficacy of Goshajinkigan for Peripheral Neurotoxicity of Oxaliplatin in Patients with Advanced or Recurrent Colorectal Cancer

Table 3

Frequency of peripheral neuropathy at a total oxaliplatin dose of 500 mg m⁻².

	Group A,		Group B,		Group C,		Group D (𝑛=36)
	(𝑛=10)		(𝑛=6)		(𝑛=19)
	Percentage	P-value	Percentage	P-value	Percentage	P-value
All grades	50.0	.002	100	.463	78.9	.178	91.7
Grade 2	0	.130	16.7	.873	5.3	.156	19.4
Grade 3	0	.345	33.3	.080	0	.196	8.3

Group A, GJG; Group B, Ca/Mg; Group C, GJG + Ca/Mg; Group D, no therapy.
P-values are for Groups A, B and C versus. Group D by the 𝜒²-test.
GJG, goshajinkigan; Ca, calcium gluconate; Mg, magnesium sulfate.
n: numbers are patients received over 500 mg m⁻² dose of total oxaliplatin.